Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
April 20, 2022 at 7:30 AM EDT
PDF Version
95% Efficacy overall for prevention of severe COVID-19 disease including related deaths
https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-announces-self-amplifying-covid-19-mrna-vaccine